Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart.

Ihlo CA, Lauritzen T, Sturis J, Skyggebjerg O, Christiansen JS, Laursen T.

Diabet Med. 2011 Feb;28(2):230-6. doi: 10.1111/j.1464-5491.2010.03149.x.

PMID:
21219436
[PubMed - indexed for MEDLINE]
2.

Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.

Clin Ther. 2009 May;31(5):980-7. doi: 10.1016/j.clinthera.2009.05.010.

PMID:
19539098
[PubMed - indexed for MEDLINE]
3.

Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.

Lepore G, Dodesini AR, Nosari I, Trevisan R.

Diabetes Care. 2003 Apr;26(4):1321-2. No abstract available.

PMID:
12663625
[PubMed - indexed for MEDLINE]
4.

The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.

Diabetes Technol Ther. 2008 Dec;10(6):479-85. doi: 10.1089/dia.2008.0019.

PMID:
19049377
[PubMed - indexed for MEDLINE]
5.

Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.

Diabetes Care. 2009 Jul;32(7):1170-6. doi: 10.2337/dc08-1874. Epub 2009 Apr 23. Erratum in: Diabetes Care. 2009 Oct;32(10):1944.

PMID:
19389820
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Impaired absorption of insulin aspart from lipohypertrophic injection sites.

Johansson UB, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, Lins PE.

Diabetes Care. 2005 Aug;28(8):2025-7. No abstract available.

PMID:
16043749
[PubMed - indexed for MEDLINE]
7.

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.

Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.

Diabetes Care. 1998 Oct;21(10):1627-31.

PMID:
9773721
[PubMed - indexed for MEDLINE]
8.

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.

Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group.

Diabetes Care. 2008 Feb;31(2):210-5. Epub 2007 Nov 5.

PMID:
17989308
[PubMed - indexed for MEDLINE]
9.

Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Lindholm A, Jacobsen LV.

Clin Pharmacokinet. 2001;40(9):641-59. Review.

PMID:
11605714
[PubMed - indexed for MEDLINE]
10.

A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.

Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS.

Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):216-21. doi: 10.1111/j.1742-7843.2008.00355.x. Epub 2009 Jan 20.

PMID:
19175369
[PubMed - indexed for MEDLINE]
11.

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.

Diabetes Care. 2002 Mar;25(3):439-44.

PMID:
11874927
[PubMed - indexed for MEDLINE]
12.

Insulin pump therapy in pregnant women with type 1 diabetes mellitus.

Roman G.

Rom J Intern Med. 2004;42(2):465-8. No abstract available.

PMID:
15529637
[PubMed - indexed for MEDLINE]
13.

Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.

Bragd J, von Döbeln A, Lins PE, Adamson U, Bergström J, Oskarsson P.

Diabetes Technol Ther. 2010 Sep;12(9):689-93. doi: 10.1089/dia.2010.0062.

PMID:
20687863
[PubMed - indexed for MEDLINE]
14.

Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.

Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smedegaard JS, Lauritzen T, Christiansen JS.

Diabet Med. 2008 May;25(5):585-91. doi: 10.1111/j.1464-5491.2008.02418.x.

PMID:
18445172
[PubMed - indexed for MEDLINE]
15.

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.

Diabetes Care. 2005 Mar;28(3):533-8.

PMID:
15735183
[PubMed - indexed for MEDLINE]
16.

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB.

Diabetes. 2000 Dec;49(12):2142-8.

PMID:
11118018
[PubMed - indexed for MEDLINE]
17.

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.

Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, Miselli V, Brandolini S, Fabbri T, Meandri P, Cannatà F.

Diabetes Technol Ther. 2008 Dec;10(6):495-8. doi: 10.1089/dia.2008.0013.

PMID:
19049379
[PubMed - indexed for MEDLINE]
18.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. doi: 10.1089/dia.2010.0184. Epub 2011 Feb 28.

PMID:
21355718
[PubMed - indexed for MEDLINE]
19.
20.

Bolus calculator improves long-term metabolic control and reduces glucose variability in pump-treated patients with Type 1 diabetes.

Lepore G, Dodesini AR, Nosari I, Scaranna C, Corsi A, Trevisan R.

Nutr Metab Cardiovasc Dis. 2012 Aug;22(8):e15-6. doi: 10.1016/j.numecd.2012.04.001. Epub 2012 Jun 4. No abstract available.

PMID:
22673770
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk